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This is a 60 year old female who presented with abdominal pain
and bloating. A CT scan of abdomen and pelvis in 7/2012 showed
ascites, 16 cm complex pelvic mass and omental caking. In 9/2012
she was brought to the operating room for tumor debulking, however
intraoperatively she became hypotensive and unstable. Only partial
omentectomy could be performed and pathology was consistent with
serous carcinoma from ovarian primary.
In 9/2012 she received her ﬁrst cycle of neoadjuvant carboplatin
and paclitaxel. She was premedicated (diphenhydramine 50 mg IV,
decadron 20 mg IV and famotidine 20 mg IV) prior to starting paclitaxelIntroduction
The standard treatment for patients with ovarian cancer is the
combination of platinum and taxane chemotherapy. However, one
of the limitations in using paclitaxel and docetaxel is the hypersensi-
tivity reaction (HSR) that patients' experience. Despite pretreatment
during initial infusion severe HSR could occur in 2% of the cases. For
patients who develop HSR to paclitaxel there is the danger of cross
reactivity with docetaxel and has been reported to be as high as 90%
as previously published by Dizon et al. (2006).
The etiology of HSR to paclitaxel and docetaxel is poorly under-
stood. It is believed that the solvent Cremophor EL in paclitaxel, and
polysorbate80 in docetaxel may be the cause of HSR. Yet, others
have demonstrated that HSR maybe secondary to the direct effect
of the taxane itself (Essayan et al., 1996) and not the diluents. There
have been several reports that nab-paclitaxel can be safely adminis-
tered after HSR to paclitaxel (Fader and Rose, 2009) but no reported
cases of safely administering nab-paclitaxel after HSR to both pacli-
taxel and docetaxel.5, Indianapolis, IN 46202, USA.
n).
Inc. Open access under CC BY-NC-ND licens(175 mg/m2/3 h) however, 20 min into the infusion she developed urti-
carial rash and went to respiratory distress with O2 saturation of 60%
on room air. Infusion was discontinued and she received epinephrine
and solumedrol with resolution of symptoms and improvement of vital
signs. In 10/2012, she received second cycle of carboplatin (5 AUC)with-
out complications and received docetaxel (75 mg/m2/1 h) as a replace-
ment for paclitaxel. Despite receiving premedication with decadron
20 mg IV and diphenhydramine 25 mg IV, 10 min into the docetaxel in-
fusion she developed dyspnea and hypoxia. Given second episode of HSR
with taxane, we administered liposomal doxorubicin on her third cycle
of chemotherapy; but unfortunately she also developed HSR to liposo-
mal doxorubicin.
Given her history of HSR to paclitaxel, docetaxel and liposomal
doxorubicin, a decision was made to try nab-paclitaxel. In 11/2012
she received her ﬁrst cycle of nab-paclitaxel (100 mg/m2/30 min) in
an outpatient setting after receiving dexamethasone 20 mg IV and di-
phenhydramine 50 mg IV without evidence of HSR. She subsequently
received two more cycles without complications. After six cycles of
carboplatin and three cycles of nab-paclitaxel, a repeat CT showed
good tumor response and she had an uncomplicated optimal, interval
tumor debulking.Discussion
First line treatment for ovarian cancer is the combination of plati-
num and taxane however, one of the treatment limiting factors of
taxanes is the high risk of developing HSR which could be life threat-
ening. The inability to tolerate and receive a taxane regimen can have
a negative impact in patient's overall survival. Acknowledging the
clinical importance of taxanes, this patient elected to undergo another
attempt at receiving a taxane after developing HSR to paclitaxel ande.
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and docetaxel but not nab-paclitaxel. One may conclude that patients'
who react to both paclitaxel and docetaxel may be reacting to the
taxane component and not to the diluents and therefore at higher risk
of mounting a HSR if treated with nab-paclitaxel. To the contrary, this
patient was safely treated with nab-paclitaxel after HSR to both pacli-
taxel and docetaxel which supports the idea that the diluents may be
the true cause of HSR and not the taxane component itself.
Given the known risk of HSR to paclitaxel and docetaxel, pre-
medication has become the standard of care. However several case
reports have been published on the failure of preventing HSR to pac-
litaxel despite premedication (Del Priore et al., 1995). Options after
HSR to paclitaxel include desensitization or changing the chemother-
apy regimen. Many physicians would choose to change the paclitaxel
to docetaxel and allow for continued treatment with a taxane. Only
case reports have been published of physicians directly changing to
nab-paclitaxel (Fader and Rose, 2009) after HSR to paclitaxel and
to our knowledge there have been no reported cases of using nab-
paclitaxel after HSR to both paclitaxel and docetaxel.
Nab-paclitaxel may not be the treatment of choice after HSR to
paclitaxel as little is known about its effectiveness in ovarian cancer.
Nab-paclitaxel is a solvent free, albumin bound paclitaxel that is
administered without requiring premedication. Although there are
no studies that show equivalent effectiveness of nab-paclitaxel to
paclitaxel or docetaxel, there is a phase II GOG trial (Coleman et al.,2011) that has demonstrated that nab-paclitaxel may be effective in
patients who have recurrent or persistent platinum resistant ovarian
cancer.
We present the ﬁrst case report of successfully re-treating a patient
with severe HSR to paclitaxel and docetaxel with Nab-paclitaxel in
order to continue treating a patient with a taxane.Conﬂict of interest
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